Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],229,7476,DB01454,"3,4-Methylenedioxymethamphetamine"
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],3636,7477,DB01454,"3,4-Methylenedioxymethamphetamine"
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],92,7478,DB01454,"3,4-Methylenedioxymethamphetamine"
,30967099,AUC0-∞,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],3636,7479,DB01454,"3,4-Methylenedioxymethamphetamine"
,30967099,AUC0-∞,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],1544,7480,DB01454,"3,4-Methylenedioxymethamphetamine"
,11471875,half-life,In one patient the 4-MTA concentration was determined in a series of plasma samples and this allowed a presumptive half-life of approximately 7 h to be estimated.,Analysis of 4-methylthioamphetamine in clinical specimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11471875/),h,7,23795,DB01454,"3,4-Methylenedioxymethamphetamine"
,24141857,Cmax,"After 2.5 mg/kg MDMA, mean MDMA Cmax was 164 ± 47.1 ng/ml, HHMA and HMMA were major metabolites, and <20% of MDMA was metabolized to MDA.","Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141857/),[ng] / [ml],164,26137,DB01454,"3,4-Methylenedioxymethamphetamine"
,17080504,signal-to-noise ratio,The calibration curves prepared with 1-methyl-3-phenylpropylamine (MPPA) as an internal standard showed good linearity (r = 0.999) with 0.36-0.83 ng/mL detection limit at a signal-to-noise ratio of 3.,"A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),,3,29104,DB01454,"3,4-Methylenedioxymethamphetamine"
,17080504,C(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),[ng] / [ml],426,29105,DB01454,"3,4-Methylenedioxymethamphetamine"
,17080504,C(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),[ng] / [ml],39,29106,DB01454,"3,4-Methylenedioxymethamphetamine"
,17080504,T(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),min,20,29107,DB01454,"3,4-Methylenedioxymethamphetamine"
,17080504,T(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),min,100,29108,DB01454,"3,4-Methylenedioxymethamphetamine"
>,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39088,DB01454,"3,4-Methylenedioxymethamphetamine"
<,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39089,DB01454,"3,4-Methylenedioxymethamphetamine"
,15319342,elimination half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,4.8,39090,DB01454,"3,4-Methylenedioxymethamphetamine"
,15319342,half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,14.8,39091,DB01454,"3,4-Methylenedioxymethamphetamine"
>,26395866,R/S ratios,"R/S ratios were >1 for all analytes after 24 hours, independent of the initial chiral preference.","Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26395866/),,1,39803,DB01454,"3,4-Methylenedioxymethamphetamine"
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],1.0,44209,DB01454,"3,4-Methylenedioxymethamphetamine"
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],2.5,44210,DB01454,"3,4-Methylenedioxymethamphetamine"
> or =,18089653,overall extraction efficiencies,"At 3 concentrations spanning the linear dynamic range of the assay, mean overall extraction efficiencies from plasma were > or =85% for all compounds of interest.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85,44211,DB01454,"3,4-Methylenedioxymethamphetamine"
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85.6,44212,DB01454,"3,4-Methylenedioxymethamphetamine"
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,107.2,44213,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],916- 1363,60715,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],1833-3546,60716,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],5979-7948,60717,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"6673-14,869",60718,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"23,428-29,433",60719,DB01454,"3,4-Methylenedioxymethamphetamine"
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"52,735-66,525",60720,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,half-life,The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 h for (-)-(R)-MDMA and 2.2 +/- 0.8 h for (+)-(S)-MDMA.,"Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),h,2.5,63431,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,half-life,The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 h for (-)-(R)-MDMA and 2.2 +/- 0.8 h for (+)-(S)-MDMA.,"Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),h,2.2,63432,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,AUC S/R ratios,"The mean (+/- SD) AUC S/R ratios of MDMA and MDA were 0.70 +/- 0.05 and 3.1 +/- 0.8, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,0.70,63433,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,AUC S/R ratios,"The mean (+/- SD) AUC S/R ratios of MDMA and MDA were 0.70 +/- 0.05 and 3.1 +/- 0.8, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,3.1,63434,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,20,63435,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,12,63436,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,3,63437,DB01454,"3,4-Methylenedioxymethamphetamine"
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,6,63438,DB01454,"3,4-Methylenedioxymethamphetamine"
,22832282,T(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),h,0.25,65214,DB01454,"3,4-Methylenedioxymethamphetamine"
,22832282,C(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),[ng] / [ml],1206,65215,DB01454,"3,4-Methylenedioxymethamphetamine"
,19417716,elimination half-life,The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours).,"Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine (""ecstasy"") disposition and metabolism in squirrel monkeys and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417716/),h,2-3,66347,DB01454,"3,4-Methylenedioxymethamphetamine"
,19417716,elimination half-life,The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours).,"Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine (""ecstasy"") disposition and metabolism in squirrel monkeys and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417716/),h,6-9,66348,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,maximum plasma concentrations (C(max)),"Mean +/- standard deviation maximum plasma concentrations (C(max)) of 162.9 +/- 39.8 and 171.9 +/- 79.5 ng/mL were observed for MDMA and HMMA, respectively, after low-dose MDMA.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],162.9,67224,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,maximum plasma concentrations (C(max)),"Mean +/- standard deviation maximum plasma concentrations (C(max)) of 162.9 +/- 39.8 and 171.9 +/- 79.5 ng/mL were observed for MDMA and HMMA, respectively, after low-dose MDMA.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],171.9,67225,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,Cmax,"After the high dose, mean MDMA Cmax significantly increased to 291.8 +/- 76.5 ng/mL, whereas mean HMMA C(max) was unchanged at 173.5 +/- 66.3 ng/mL.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],291.8,67226,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,C(max),"After the high dose, mean MDMA Cmax significantly increased to 291.8 +/- 76.5 ng/mL, whereas mean HMMA C(max) was unchanged at 173.5 +/- 66.3 ng/mL.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],173.5,67227,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,C(max),Mean MDA C(max) were 8.4 +/- 2.1 (low) and 13.8 +/- 3.8 (high) ng/mL.,"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],8.4,67228,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,C(max),Mean MDA C(max) were 8.4 +/- 2.1 (low) and 13.8 +/- 3.8 (high) ng/mL.,"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],13.8,67229,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,Cmax,"HMA Cmax were 3.5 +/- 0.4 and 3.9 +/- 0.9 ng/mL after the low and high doses, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],3.5,67230,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,Cmax,"HMA Cmax were 3.5 +/- 0.4 and 3.9 +/- 0.9 ng/mL after the low and high doses, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],3.9,67231,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,7 to 8,67232,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,10.5 to 12.5,67233,DB01454,"3,4-Methylenedioxymethamphetamine"
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,11.5 to 13.5,67234,DB01454,"3,4-Methylenedioxymethamphetamine"
,19679675,maximum MDMA concentrations (C(max)),"After 2 mg/kg, maximum MDMA concentrations (C(max)) were approximately 200 ng/ml for intraperitoneal and subcutaneous routes, but less for the oral route.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),[ng] / [ml],200,79089,DB01454,"3,4-Methylenedioxymethamphetamine"
<,19679675,plasma half-lives,"MDMA plasma half-lives were <1 h for low-dose groups, whereas HMMA and MDA half-lives were >2 h.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),h,1,79090,DB01454,"3,4-Methylenedioxymethamphetamine"
>,19679675,half-lives,"MDMA plasma half-lives were <1 h for low-dose groups, whereas HMMA and MDA half-lives were >2 h.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),h,2,79091,DB01454,"3,4-Methylenedioxymethamphetamine"
,14871155,distribution volume,"Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%).",Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),[l] / [kg],4,85473,DB01454,"3,4-Methylenedioxymethamphetamine"
,14871155,elimination half-life,The elimination half-life is 6-12 hours.,Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),h,6-12,85474,DB01454,"3,4-Methylenedioxymethamphetamine"
,14871155,pKa,"Amfetamine and related compounds are weak bases, with a pKa around 9.9, and a relatively low molecular weight.",Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),,9.9,85475,DB01454,"3,4-Methylenedioxymethamphetamine"
,11559034,C(max),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],154.5,88271,DB01454,"3,4-Methylenedioxymethamphetamine"
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1990.9,88272,DB01454,"3,4-Methylenedioxymethamphetamine"
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],181.6,88273,DB01454,"3,4-Methylenedioxymethamphetamine"
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1465.9,88274,DB01454,"3,4-Methylenedioxymethamphetamine"
,11568088,Salivary concentrations,Salivary concentrations of MDMA were 1728.9-6510.6 microg/L and peaked at 1.5 h after drug intake.,"Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568088/),[μg] / [l],1728.9-6510.6,127330,DB01454,"3,4-Methylenedioxymethamphetamine"
,11568088,saliva-to-plasma ratio,"The saliva-to-plasma ratio was 32.3-1.2, with a peak of 18.1 at 1.5 h after drug administration.","Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568088/),,32.3-1.2,127331,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],236.4,146037,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],130.9,146038,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,2.4,146039,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,1.8,146040,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,8.6,146041,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,7.7,146042,DB01454,"3,4-Methylenedioxymethamphetamine"
,10381769,half-life,Amphetamine half-life was 15 h.,"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,15,146043,DB01454,"3,4-Methylenedioxymethamphetamine"
,10388483,plasma half-life,"The plasma concentrations of (R)-MDMA exceeded those of the S-enantiomer [ratio R:S of the area under the curve (AUC), 2.4 +/- 0.3], and the plasma half-life of (R)-MDMA (5.8 +/- 2.2 h) was significantly longer than that of the S-enantiomer (3.6 +/- 0.9 h).","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),h,5.8,148701,DB01454,"3,4-Methylenedioxymethamphetamine"
,10388483,plasma half-life,"The plasma concentrations of (R)-MDMA exceeded those of the S-enantiomer [ratio R:S of the area under the curve (AUC), 2.4 +/- 0.3], and the plasma half-life of (R)-MDMA (5.8 +/- 2.2 h) was significantly longer than that of the S-enantiomer (3.6 +/- 0.9 h).","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),h,3.6,148702,DB01454,"3,4-Methylenedioxymethamphetamine"
,10388483,recovery,"The majority of the recovered material in urine was excreted within 24 h after dosing, with the recovery of (R)-MDMA (21.4% +/- 11.6%) being significantly greater than that of (S)-MDMA (9.3% +/- 4.9%), and with (S)- and (R)-MDA accounting for 1.4% +/- 0.5% and 1.0% +/- 0.3% of the dose, respectively.","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),%,21.4,148703,DB01454,"3,4-Methylenedioxymethamphetamine"
,10388483,recovery,"The majority of the recovered material in urine was excreted within 24 h after dosing, with the recovery of (R)-MDMA (21.4% +/- 11.6%) being significantly greater than that of (S)-MDMA (9.3% +/- 4.9%), and with (S)- and (R)-MDA accounting for 1.4% +/- 0.5% and 1.0% +/- 0.3% of the dose, respectively.","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),%,9.3,148704,DB01454,"3,4-Methylenedioxymethamphetamine"
over,18396472,recoveries,The recoveries were over 90% in all biological samples tested.,"Analysis of amphetamine-type stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange column-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18396472/),%,90,178357,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],348.0,195990,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],68,195991,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,29.,195992,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243,195993,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],401.8,195994,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],671.1,195995,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,159.9,195996,DB01454,"3,4-Methylenedioxymethamphetamine"
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243.4,195997,DB01454,"3,4-Methylenedioxymethamphetamine"
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,3,202858,DB01454,"3,4-Methylenedioxymethamphetamine"
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,6-9,202859,DB01454,"3,4-Methylenedioxymethamphetamine"
,15999148,plasma ratio,"MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5 / 100, similar to that in humans.",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),,3-5,202860,DB01454,"3,4-Methylenedioxymethamphetamine"
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,2.15,216678,DB01454,"3,4-Methylenedioxymethamphetamine"
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,7.89,216679,DB01454,"3,4-Methylenedioxymethamphetamine"
,12208028,peak concentration,"Resultant plasma concentrations varied from 21 to 295 ng/ml, with an average peak concentration of 178 ng/ml observed between 2 and 4h after administration.","Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12208028/),[ng] / [ml],178,221640,DB01454,"3,4-Methylenedioxymethamphetamine"
,17474141,flow rate,"The DIB-derivatives of MDMA, MDA and the internal standard, 1-methyl-3-phenylpropylamine (MPPA), were isocratically separated on an ODS column using a mixture of 50 mm phosphate buffer (pH 7.0)-acetonitrile-methanol-2-propanol (50:45:5:2, v/v/v/v %) as an eluent at a flow rate of 1.5 mL/min.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ml] / [min],1.5,228860,DB01454,"3,4-Methylenedioxymethamphetamine"
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.2,228861,DB01454,"3,4-Methylenedioxymethamphetamine"
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),,4.2,228862,DB01454,"3,4-Methylenedioxymethamphetamine"
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.3,228863,DB01454,"3,4-Methylenedioxymethamphetamine"
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],4.8,228864,DB01454,"3,4-Methylenedioxymethamphetamine"
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.00,233432,DB01454,"3,4-Methylenedioxymethamphetamine"
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.,233433,DB01454,"3,4-Methylenedioxymethamphetamine"
,18794647,recovery half-life,CYP2D6 activity recovered after 10 days with a recovery half-life of 46.6 hours.,"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),h,46.6,233434,DB01454,"3,4-Methylenedioxymethamphetamine"
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,2.4,251481,DB01454,"3,4-Methylenedioxymethamphetamine"
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,4.9,251482,DB01454,"3,4-Methylenedioxymethamphetamine"
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),,1.8,251483,DB01454,"3,4-Methylenedioxymethamphetamine"
,19164498,pseudo-steady state levels,MDMA (100 mg) was given orally while blood alcohol concentration was maintained at pseudo-steady state levels of approximately 0.6 per thousand for 3 h by a 10% intravenous ethanol clamp.,Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164498/),1/[thousand],0.6,259565,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P ratios,Median (range) OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA.,"Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,5.6,267157,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P ratios,Median (range) OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA.,"Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,3.7,267158,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,5,267159,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,6,267160,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,3,267161,DB01454,"3,4-Methylenedioxymethamphetamine"
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,4,267162,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"21,470",270748,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],2229,270749,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"20,793",270750,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],876,270751,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,13.9,270752,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.0,270753,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,9.2,270754,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.3,270755,DB01454,"3,4-Methylenedioxymethamphetamine"
,19874650,total urinary excretion,"In the first 24 h, 30.2-34.3% total urinary excretion occurred.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),%,30.2-34.3,270756,DB01454,"3,4-Methylenedioxymethamphetamine"
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,136,271167,DB01454,"3,4-Methylenedioxymethamphetamine"
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,144,271168,DB01454,"3,4-Methylenedioxymethamphetamine"
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,90,271169,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,C(max),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[ng] / [ml],188.8,273634,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,time to reach C(max) (t(max)),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,2.0,273635,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,AUC from 0 to 25 hours,"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[h·mg] / [ml],2645.2,273636,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,25.4,273637,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,6.6,273638,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.018,273639,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.998,273640,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,recovery half-life,"CYP2D6 activity recovered after 10 days to 90% of baseline activity, with a recovery half-life of 36.6 ± 22.9 hours.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,36.6,273641,DB01454,"3,4-Methylenedioxymethamphetamine"
,21456632,recovery half-life,Male subjects showed a shorter recovery half-life (27.6 ± 25.1 hours).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,27.6,273642,DB01454,"3,4-Methylenedioxymethamphetamine"
